Contributions
Abstract: PB1510
Type: Publication Only
Session title: Chronic myeloid leukemia - Biology & Translational Research
Background
The efficacy of Tyrosine Kinase inhibitors (TKI) treatment can be accurately evaluated by a molecular monitoring based on the quantification of BCR-ABL1.
Aims
This study was carried out to assess the minimal residual disease in Tunisian patients with chronic myeloid leukemia (CML) treated with TKI therapy in routine clinical practice in Tunisia to identify potentially eligible for treatment discontinuation, based on a molecular response (MR) on the international scale (IS).
Methods
A five-year retrospective study was carried out in the Hospital University of Sfax, south of Tunisia including all CML patients in the chronic phase at diagnosis, treated with TKI for a minimum duration of 6 months. Quantitative assessment of the BCR-ABL transcript was performed using the Cepheid Xpert BCR-ABL ultra assay. Molecular response and outcome were evaluated; according to the European Leukemia Net guidelines.
Results
A total of 162 CML patients were carried out. The median age was 50 years, the sex ratio M/F was 1.62. The rate of cumulative EMR; MMR and DMR was 80.8%; 73.8% and 55.9% respectively. According to the ELN criteria, 141 CML patients were evaluable. Optimal, suboptimal response, and failure were noted in 81 (57.4%), 33(23.4%) and 27(19.1%) patients, respectively. Overall survival (OS) and progression-free survival (PFS) was 96.3% and 85%. Risk factors for event (death/progression) were lack of EMR, MMR and DMR (P<0.05). Among 149 patients with sustained DMR; 14 (8.6%) CML patients have discontinued TKI therapy.
Conclusion
Despite the limit of our study (duration and size), the available real-life molecular responses with TKI therapy should be considered to identify potentially CML patients eligible for discontinuation of TKI therapy.
Keyword(s): Chronic myeloid leukemia, Minimal residual disease (MRD), Molecular response, Survival
Abstract: PB1510
Type: Publication Only
Session title: Chronic myeloid leukemia - Biology & Translational Research
Background
The efficacy of Tyrosine Kinase inhibitors (TKI) treatment can be accurately evaluated by a molecular monitoring based on the quantification of BCR-ABL1.
Aims
This study was carried out to assess the minimal residual disease in Tunisian patients with chronic myeloid leukemia (CML) treated with TKI therapy in routine clinical practice in Tunisia to identify potentially eligible for treatment discontinuation, based on a molecular response (MR) on the international scale (IS).
Methods
A five-year retrospective study was carried out in the Hospital University of Sfax, south of Tunisia including all CML patients in the chronic phase at diagnosis, treated with TKI for a minimum duration of 6 months. Quantitative assessment of the BCR-ABL transcript was performed using the Cepheid Xpert BCR-ABL ultra assay. Molecular response and outcome were evaluated; according to the European Leukemia Net guidelines.
Results
A total of 162 CML patients were carried out. The median age was 50 years, the sex ratio M/F was 1.62. The rate of cumulative EMR; MMR and DMR was 80.8%; 73.8% and 55.9% respectively. According to the ELN criteria, 141 CML patients were evaluable. Optimal, suboptimal response, and failure were noted in 81 (57.4%), 33(23.4%) and 27(19.1%) patients, respectively. Overall survival (OS) and progression-free survival (PFS) was 96.3% and 85%. Risk factors for event (death/progression) were lack of EMR, MMR and DMR (P<0.05). Among 149 patients with sustained DMR; 14 (8.6%) CML patients have discontinued TKI therapy.
Conclusion
Despite the limit of our study (duration and size), the available real-life molecular responses with TKI therapy should be considered to identify potentially CML patients eligible for discontinuation of TKI therapy.
Keyword(s): Chronic myeloid leukemia, Minimal residual disease (MRD), Molecular response, Survival